JP6943561B2 - Drug administration device - Google Patents

Description

The present invention relates to drug administration equipment to administer drugs to a patient.

As disclosed in Patent Document 1, the drug administration device includes a syringe, a control unit, and an actuator for operating the plunger of the syringe, and a predetermined amount of the drug in the syringe is given to the patient at predetermined time intervals. Administer. By the way, when administering a drug to a patient, it is necessary to surely prevent erroneous administration due to a mistake (misidentification, misunderstanding, etc.) of the drug.

Therefore, medical professionals such as doctors and nurses confirm drugs to be used by various methods. For example, in a medical facility, a barcode or IC tag (RFID tag) having an identification code is stored in a state of being attached to a drug container, and a medical worker reads the identification code with a reader at the time of use. Drugs are being selected and confirmed.

JP-A-2002-136594

However, in the conventional confirmation method, there is a possibility that the selection of the drug may be erroneous even if the container is identified by the reader due to causes such as incorrect sticking of the barcode or IC tag, poor reading of the identification code due to dirt, and the like. In addition, attaching a barcode or IC tag to the container causes inconveniences such as labor and cost.

The present invention was made in view of the above circumstances, to identify the medication to be administered device actually by the optical measurement, drug administration equipment that can more reliably prevent erroneous administration of the drug The purpose is to provide.

In order to achieve the above object, the present invention is a drug administration device that administers a drug stored in a syringe to a supply target, wherein an optical measurement unit that performs optical measurement on the syringe and the syringe The control unit that analyzes the output signal to identify the drug of the syringe, the notification unit that notifies the information of the drug of the syringe specified by the control unit, the light emitting element and the light receiving element of the optical measurement unit, and the above. a light guide path provided between the syringe body of the syringe, is fixed to the syringe body, said by shielding the portion contacting holding the syringe body, the said optical measurement portion by shielding the light path optical It is characterized by including a holder for assisting measurement.

According to the above, since the drug administration device performs optical measurement on the syringe by the optical measurement unit and analyzes the signal to identify the drug, it is possible to directly identify the drug actually administered by the device. Become. This makes it possible to more reliably prevent erroneous administration of drugs, and by eliminating the need for confirmation methods using barcodes and IC tags, the labor and cost of using barcodes and IC tags can be reduced. can do. Alternatively, even when a confirmation method using a barcode or an IC tag is used in combination, the drug can be appropriately administered by preventing an error in affixing the identification code to the container, an error in selecting the drug due to improper reading of the identification code, and the like.

Further, the control unit includes an analysis unit that analyzes the signal of the optical measurement unit to obtain a measurement absorption spectrum which is a distribution of wavelength and absorbance, and a drug identification unit that specifies a drug of the syringe based on the measurement absorption spectrum. , Are preferably provided.

The drug administration device can acquire the optical characteristics of the drug, which is the relationship between the wavelength and the absorbance, by analyzing the signal of the optical measurement unit by the analysis unit and obtaining the measured absorbance spectrum. Therefore, the drug identification unit can easily identify a drug that matches the analyzed optical characteristics.

In addition to the above configuration, the drug identification unit refers to a drug database in which a plurality of types of drug information including a unique determination absorption spectrum for determining the measured absorption spectrum are registered, and the measured absorption spectrum is the said. It is preferable to identify the drug in the syringe based on matching or approximating the absorption spectrum for determination.

By using a drug database having a judgment absorption spectrum for each drug, the drug identification unit can easily and quickly determine whether the measured absorption spectrum matches (or approximates) the judgment absorption spectrum for each drug. Can be determined.

Further, when the drug identification unit determines that all the measured absorption spectra do not match the plurality of determination absorption spectra stored in the drug database, the control unit via the notification unit. It is advisable to notify that the drug in the syringe is not registered.

That is, the drug identification unit can easily determine that the drug is not registered in the drug database and notify the user to that effect.

Furthermore, it is preferable that the analysis unit removes the absorption spectrum of the syringe when analyzing the signal.

Since the signal measured by the optical measuring unit also includes the absorption spectrum of the syringe storing the drug, the drug administration device obtains an accurate measured absorption spectrum by removing the absorption spectrum of this syringe. Is possible.

Then, the control unit is configured to set a limit value of the dose or administration rate corresponding to the specified drug of the syringe to limit the range of the dose or administration rate of the drug set by the user. good.

The drug administration device can appropriately administer the drug to the administration target by setting the limit value of the dose or the administration rate of the drug based on the specified drug.

Further, it is preferable that the optical measuring unit is arranged at a position facing the syringe in a state of being set in the device.

As a result, the drug administration device can measure the drug in the syringe in the state set in the device, and can more reliably identify the drug and prevent erroneous administration.

Further, the control unit may have a measurement unit control unit that drives the optical measurement unit to automatically perform the optical measurement when the syringe is set in the device.

Thereby, the drug administration device can prevent the user from forgetting to operate and identify the drug in the syringe set in the device. In addition, the user's operation is simplified and the usability of the device is improved.

Drug administration equipment according to the present invention, to identify the medication to be administered device actually by the optical measurement, it is possible to more reliably prevent erroneous administration of the drug.

It is a top view which shows the whole structure of the syringe pump which is the drug administration apparatus which concerns on one Embodiment of this invention. It is a functional block diagram of the syringe pump of FIG. It is explanatory drawing explaining the analysis of the absorbance spectrum by the analysis part. It is explanatory drawing explaining the identification of the drug by the drug identification part. It is a flowchart which shows the drug administration method of a syringe pump. It is explanatory drawing which shows the infusion set which applied the liquid feed pump which is the drug administration apparatus which concerns on application example.

Hereinafter, exemplified by preferred embodiments with the drug administration equipment according to the present invention will be described in detail with reference to the accompanying drawings.

The drug administration device 10 is a medical device that automatically or manually administers a drug ME (see FIG. 2) to a patient (supply target), and is a stationary syringe pump, infusion pump, or the like used in a medical facility or the like. It is an insulin pump that is carried in daily life. The drug ME administered by the drug administration device includes liquid drugs such as anticancer drugs, chemotherapeutic agents, anesthetics, antibiotics, insulin, blood products, and nutritional supplements, as well as gel-like drugs such as enteral nutritional supplements. Drugs can be given.

As shown in FIG. 1, for example, the drug administration device 10 includes a syringe 12 (storage unit) that stores the drug ME, and a device main body 20 that controls the operation of the syringe 12 to supply the drug ME to the patient. Syringe pump 10 can be mentioned. Hereinafter, the syringe pump 10 will be typically taken up and described.

The syringe pump 10 supplies the drug ME from the syringe 12 at a dose and administration rate set by a medical worker (user) such as a doctor or a nurse. Further, the syringe pump 10 according to the present embodiment has a function of specifying the type and concentration of the drug ME in the syringe 12 by optical measurement in a state where the syringe 12 is set in the apparatus main body 20 (embedded state). ing. This makes it possible to reliably prevent the drug ME from being accidentally administered to the patient.

Specifically, the syringe 12 of the syringe pump 10 is formed in a dedicated shape (a cylindrical shape that is short in the axial direction but large in the radial direction) that can be set in the apparatus main body 20. The syringe 12 has a syringe body 14 and a plunger 16 that is housed so as to be relatively movable with respect to the syringe body 14. It is preferable that a plurality of syringes 12 having a constant thickness and different volumes of the drug ME to be stored are prepared. The syringe pump 10 may have a configuration in which a commercially available syringe 12 can be set in the apparatus main body 20.

The syringe body 14 is formed in a cylindrical shape and has a storage space 15 inside which the drug ME can be stored. The tip of the syringe body 14 has a conical shape that narrows toward the tip, and a protrusion 14a is provided at the center thereof. The protrusion 14a communicates the storage space 15 with the outside, and the tube 18 is connected and fixed when the syringe 12 is set or the like.

The tube 18 has a flow path 18a inside which the drug ME can flow, and is connected to a drug introduction portion (indwelling needle or the like) separately provided for the patient. Then, the flow path 18a and the drug introduction section administer the drug ME flowing out of the syringe pump 10 to the patient.

The plunger 16 is long in the axial direction and is formed in a cross-shaped rod shape in a cross-sectional view, and is provided with a gasket 17 at its tip. The gasket 17 is inserted into the storage space 15 and is in liquid-tight and slidable contact with the inner surface of the syringe body 14 constituting the storage space 15. With the syringe 12 set in the device body 20, the plunger 16 advances relative to the syringe body 14 under the drive control of the device body 20 and pushes out the drug ME in the storage space 15. A flange 16a is formed at the base end of the plunger 16 so that the apparatus main body 20 can be easily pushed out.

On the other hand, the apparatus main body 20 of the syringe pump 10 is formed in a box shape having a size that can be carried by a patient. The apparatus main body 20 includes a resin case 22 for accommodating the syringe 12. The case 22 is a mechanism in which a rectangular shape having rounded corners is formed, an arrangement portion 24 for arranging and fixing the syringe 12 and various configurations for driving and controlling the set syringe 12 adjacent to the arrangement portion 24 are housed. It has a part 26 and.

In the arrangement portion 24, only the upper surface (one surface) side of the case 22 is cut out so that the syringe 12 can be easily set, so that the inside of the lower surface (the other surface) is open, and the inner surface of the open portion is open. Is exposed. The inner surface of the arrangement portion 24 is provided with a syringe holding wall (not shown) that is formed to match the shape of the syringe body 14 and fixes the syringe body 14.

Further, the arrangement portion 24 is provided with a holder 28 for fixing the axially intermediate position (closer to the tip side) of the syringe body 14. For example, the holder 28 is formed in an arch shape in a cross-sectional view, and has a hinge 28a at the end on the mechanical portion 26 side so that the opposite end can be locked and separated from the syringe holding wall. It is composed. The holder 28 contacts and holds the syringe body 14 to shield the portion from light, and assists the optical measurement by the optical measuring unit 38 described later.

Further, the arrangement portion 24 arranges the movable body 44 on the base end side of the flange 16a of the plunger 16. The movable body 44 is provided over both the arrangement portion 24 and the mechanism portion 26, and constitutes a part of the pusher drive mechanism 32 provided in the mechanism portion 26.

The mechanism portion 26 of the apparatus main body 20 is entirely covered by the case 22 in contrast to the arrangement portion 24. Inside the mechanism unit 26, a power supply unit 30, the pusher drive mechanism 32 described above, a drive source 34, a control circuit 36, and an optical measurement unit 38 are provided. Further, the case 22 of the mechanism unit 26 is provided with a monitor 40 and an operation button group 42.

For example, a dry battery or a secondary battery is applied to the power supply unit 30. The monitor 40 is a notification unit that displays various information for the syringe pump 10 to administer the drug ME, and for example, a color liquid crystal display is applied. The operation button group 42 is composed of a plurality of pressing buttons, and is used by the user to set parameters of the syringe pump 10.

The pusher drive mechanism 32 in the mechanism unit 26 includes the above-mentioned movable body 44 and the screw member 46 to which the movable body 44 is attached, and is a ball screw mechanism that converts the rotation of the screw member 46 into the linear motion of the movable body 44. It is configured as. The screw member 46 is provided parallel to the axial direction of the plunger 16 (direction of arrow A), and both ends thereof are pivotally supported by bearings (not shown). A gear 46a is fixed to one end of the screw member 46, and the driving force of the drive source 34 is transmitted through the gear 46a.

The movable body 44 has a ball (not shown) that rolls along the thread of the screw member 46, and moves in conjunction with the rotation of the screw member 46 around the axis. Before the syringe 12 is set in the arrangement unit 24, the movable body 44 moves and stands by at the base end (A2 in FIG. 1) of the arrangement unit 24 under the control of the control circuit 36. After the syringe 12 is set, as the administration of the drug ME is started, the drug ME gradually moves toward the tip end (A1 in FIG. 1) of the arrangement portion 24 at a speed controlled by the control circuit 36. At this time, the portion exposed to the arrangement portion 24 of the movable body 44 comes into contact with the plunger 16 and pushes the plunger 16 into the syringe body 14.

The drive source 34 rotates the pusher drive mechanism 32 (screw member 46) by supplying electric power under the control of the control circuit 36. As the drive source 34 of this type, for example, a stepping motor, a servo motor, or the like can be applied.

The control circuit 36 is configured in a computer having a processor, a memory, and an input / output interface (not shown), and is a control unit that controls the administration of the drug ME by the syringe pump 10. The processor executes a control program (not shown) stored in the memory to construct a functional block unit for administering the drug ME as shown in FIG. Specifically, the control circuit 36 is provided with an administration parameter setting unit 50, a syringe drive control unit 52, a measurement unit control unit 54, and a drug determination processing unit 70.

The administration parameter setting unit 50 sets various parameters in the administration of the drug ME, such as the dose, the administration rate, and the conditions for detecting obstruction, based on the operation of the operation button group 42 by the user. Each parameter is stored in the memory and read out by the control circuit 36 as needed. At the time of setting, the administration parameter setting unit 50 may display a guidance screen for guiding the input of the dose and administration rate of the drug ME on the monitor 40 to assist the input operation of the medical staff. For example, the administration parameter setting unit 50 enables the dose of the drug ME to be set in the range of 0 to 999 mL in a stationary syringe pump, an infusion pump, or the like, and the administration rate of the drug ME is 0.1 to 150 mL / h. It can be set within the range. Further, in a portable insulin pump or the like, the dose of the drug ME can be set in the range of 0 to 3 mL, and the administration rate of the drug ME can be set in the range of 0.0005 to 0.35 mL / h.

Further, the administration parameter setting unit 50 has an administration condition determination unit 50a for comparing and determining a limit value (upper limit value and lower limit value) of the dose or administration rate of the drug ME and a parameter input to the user. In the present embodiment, each limit value is set by the drug determination processing unit 70, which will be described later. The administration condition determination unit 50a permits the administration of the drug ME when the parameter is within the range of each limit value, prohibits the administration of the drug ME when the parameter is outside the range of each limit value, and monitors 40. Prompt to reset the parameters via.

The syringe drive control unit 52 calculates the drive speed and drive timing of the drive source 34 based on the dose and administration rate of the drug ME set by the administration parameter setting unit 50. A timer (not shown) is provided in the control circuit 36, and the syringe drive control unit 52 generates a control command based on the calculated administration speed of the drug ME and the time measurement of the timer, and outputs the control command to the drive source 34. do. As a result, the drive source 34 is driven at an appropriate timing and rotation speed. The drug ME may be administered at a constant rate and continuously over time, or may be administered intermittently at regular intervals.

It is preferable that the control circuit 36 displays the administration information on the monitor 40 at the time of administration of the drug ME. For example, the administration information includes the name of the drug ME, the occlusion pressure level display, the planned amount of drug administration (mL), the integrated amount of drug administration (mL), the charge amount, the injection rate (mL / h), and the injection amount (mL). ) Etc.

On the other hand, the measurement unit control unit 54 of the control circuit 36 is a functional unit that controls the operation of the optical measurement unit 38 provided in the mechanism unit 26 in order to identify the drug ME in the syringe 12. Specifically, the syringe pump 10 according to the present embodiment operates the optical measurement unit 38, analyzes the detection signal obtained by the operation by the absorptiometry, and identifies the drug ME.

As shown in FIG. 2, the optical measuring unit 38 includes a light emitting element 56, a light receiving element 58, a substrate 60, a lens 62, and the like. Further, in order to improve the detection accuracy of the reflected light, the optical measuring unit 38 blocks external light between the light emitting element 56 and the light receiving element 58 and the syringe 12, and guides the shape so as to reduce noise such as stray light. It has an optical path 38a.

As the light emitting element 56, an LED or a laser diode that irradiates irradiation light having a predetermined wavelength based on the drug ME to be measured is applied. A plurality of light emitting elements 56 may be provided in order to carry out multi-wavelength measurement for identifying a plurality of types of drug MEs.

As the light receiving element 58, a PD or the like that receives the reflected light reflected by the syringe 12 (drug ME) and outputs a detection signal is applied. The detection signal of the light receiving element 58 is subjected to processing such as A / D conversion and amplification on the substrate 60 and transmitted to the control circuit 36. Further, in the control of the optical measurement unit 38, the measurement unit control unit 54 may sequentially emit light from a plurality of light emitting elements 56 to generate a signal having multi-wavelength information based on each reflected light reflected by the syringe 12. As a result, the absorbance of the drug ME for each wavelength can be obtained satisfactorily.

As described above, the optical measurement unit 38 is not limited to the measurement structure that receives the reflected light reflected by the syringe 12. For example, the optical measurement unit 38 may adopt a measurement structure that receives the transmitted light transmitted through the syringe 12 and outputs a detection signal.

A part of the reflected light (scattered light) received by the light receiving element 58 includes information on the drug ME in the syringe 12, and the drug ME can be specified by analyzing the information on the reflected light. .. The drug determination processing unit 70 includes an analysis unit 72 that analyzes the detection signal detected by the measurement unit control unit 54, a drug identification unit 74 that identifies the drug ME based on the analysis result of the analysis unit 72, and the specified drug ME. A specific post-processing unit 76 for notifying is provided. Further, inside the drug determination processing unit 70, a drug storage unit 78 (memory storage area) that stores the drug database 80 that the drug identification unit 74 refers to when identifying the drug ME is provided.

The analysis unit 72 calculates the absorbance spectrum of the reflected light, that is, the distribution of the absorbance for each wavelength. For example, as shown in FIG. 3, the absorbance spectrum of the reflected light exhibits a wavelength pattern having an absorbance peak at one or more wavelengths. Here, in the absorption spectrum of the drug ME, the type of the drug ME is mainly indicated by the wavelength indicating the peak, and the concentration of the drug ME is indicated by the magnitude of the peak. Therefore, the drug determination processing unit 70 can specify the type of the drug ME and the concentration of the drug ME by the spectral analysis of the reflected light.

Further, when analyzing the reflected light, it is necessary to remove the influence of the reflected light reflected on the syringe body 14. Therefore, the analysis unit 72 stores the absorption spectrum of the reflected light of only the syringe body 14 set in the arrangement unit 24 in an analysis storage unit (memory storage area) (not shown). Then, the analysis unit 72 calculates the absorption spectrum of the reflected light detected by the optical measurement unit 38, and then subtracts the absorption spectrum of the syringe body 14 from the calculation result. As a result, the drug determination processing unit 70 can obtain information on the wavelength pattern of only the drug ME stored in the syringe 12 (hereinafter, referred to as the measured absorption spectrum AS).

The syringe pump 10 may employ another method (for example, spectroscopic analysis method) as a method for identifying the drug ME based on optical measurement. The spectroscopic methods include ultraviolet visible absorption spectroscopy, fluorescence spectroscopy, phosphorescence spectroscopy, atomic absorption spectroscopy, infrared absorption spectroscopy, Raman spectroscopy, X-ray spectroscopy, and nuclear magnetic resonance. Analytical methods, electron spin resonance analysis methods, microwave analysis methods and the like can be mentioned.

The drug identification unit 74 identifies the drug ME stored in the syringe 12 based on the measured absorption spectrum AS received from the analysis unit 72. At this time, the drug identification unit 74 searches the drug database 80 of the drug storage unit 78 for the drug ME corresponding to the measured absorption spectrum AS. As shown in FIG. 4, the drug database 80 contains a drug identification code 81, a drug name 82, spectrum information (hereinafter referred to as a determination absorption spectrum JS), and a dose limit value (hereinafter referred to as a dose limit value 83). ) And the limit value of the administration rate (hereinafter referred to as the administration rate limit value 84) and the like are registered in advance for each drug ME. The drug database 80 is stored in advance when the product is provided, and is appropriately updated by information communication from the outside via the network.

The determination absorption spectrum JS shows the reference wavelength pattern (wavelength and absorbance distribution information) of each drug ME. The drug identification unit 74 collates the measured absorption spectrum AS with the determination absorption spectrum JS in the search to identify the drug ME having the same pattern.

For example, the drug identification unit 74 evaluates for each drug ME that the wavelengths of the peaks of absorbance match or are similar, or that the shapes of the wavelength distributions are the same or similar, and the evaluation is the highest. Identify the type of drug ME. Thereby, the drug ME can be specified in consideration of the measurement error and the like. The drug identification unit 74 also specifies the concentration of the drug ME based on the peak for each wavelength. Further, the drug identification unit 74 is registered in the drug database 80 when the measured absorption spectrum AS does not match the determination absorption spectrum JS of all drug MEs in the drug database 80 (when the evaluation of all drug MEs is low). It is determined that the drug is not ME. That is, the non-specification of the drug ME is determined.

The specific post-processing unit 76 generates a display image based on the specific or non-specific result of the drug ME specified by the drug specific unit 74 and displays it on the monitor 40. For example, when a drug ME is specified, the name of the drug ME and a selection screen for allowing the user to select whether or not the drug ME stored in the syringe 12 is correct are displayed on the monitor 40. When the drug ME is not specified, it is notified that the drug ME is not registered in the device. At this time, the specific post-processing unit 76 may instruct the syringe drive control unit 52 to take a measure for prohibiting the administration of the drug ME.

In addition, the specific post-processing unit 76 provides the dose limit value 83 and the administration rate limit value 84 for the specified drug ME to the administration parameter setting unit 50 with reference to the drug database 80. As a result, the administration parameter setting unit 50 can limit the dose and the administration rate so that the user does not exceed the respective limit values 83 and 84 when setting the dose and the administration rate. The drug database 80 stores other information (occlusion pressure conditions, etc.) of the drug ME, and the specific post-processing unit 76 displays other information on the monitor 40 as the drug ME is specified. Processing such as providing it as a limit value set by the user may be performed.

The syringe pump 10 according to the present embodiment is basically configured as described above, and its effect will be described below together with a processing flow at the time of use.

When the syringe pump 10 is used, the syringe 12 is set in the apparatus main body 20 by the user. For example, the medical staff selects a syringe 12 (prefilled syringe) in which the drug ME is stored in advance, or selects a vial in which the drug ME is stored and causes the drug ME to flow into the storage space 15. 12 is used.

The apparatus main body 20 of the syringe pump 10 carries out the pre-stage treatment flow (drug administration method) shown in FIG. 5 after the power is turned on by the medical staff until the administration of the drug ME is started. In the pre-stage processing flow, the control circuit 36 determines whether or not the syringe 12 is set in the arrangement unit 24 (step S1). For example, the control circuit 36 detects a set of syringes 12 based on the detection of a contact sensor or proximity sensor (not shown) provided in the apparatus main body 20 or a change in the detection signal of the optical measurement unit 38.

When the set of the syringe 12 is determined in step S1, the process proceeds to step S2, the optical measurement unit 38 is driven and controlled by the measurement unit control unit 54, and the optical measurement is automatically performed on the syringe 12 (step S2: Measurement step). As a result, the measurement unit control unit 54 operates the drug determination processing unit 70 when it receives the detection signal of the reflected light of the syringe 12 acquired from the optical measurement unit 38.

Then, the analysis unit 72 of the drug determination processing unit 70 analyzes the reflected light included in the detection signal and calculates the measured absorption spectrum AS (step S3). After that, the drug identification unit 74 determines whether the measured absorption spectrum AS matches or does not match the determination absorption spectra JS of all the drug MEs registered in the drug database 80 (step S4: specific step), and the syringe 12 Search for the drug ME in. That is, it is determined whether or not the measurement result of the drug ME is registered in the drug database 80.

If the measured absorption spectrum AS and the determination absorption spectrum JS match in step S4, the process proceeds to step S5, and the identification post-processing unit 76 displays the matching drug ME information (drug name 82, etc.) on the monitor 40. .. As a result, the user can confirm the drug ME stored in the syringe 12 before administration of the drug ME. Therefore, if it is recognized that the drug ME to be administered is incorrect, it is possible to discontinue the administration of the drug ME at this point.

Further, the specific post-processing unit 76 sends the dose limit value 83 and the administration rate limit value 84 of the specified drug ME to the administration parameter setting unit 50, and the administration parameter setting unit 50 sends the limit values 83 and 84 of the drug ME, respectively. Is automatically set (step S6: administration condition setting step).

After that, the administration parameter setting unit 50 displays a guidance screen for guiding the setting of the dose and administration rate of the drug ME on the monitor 40, and causes the user to set the parameters for drug administration (step S7).

The administration condition determination unit 50a determines whether or not the input values of the dose and administration rate of the drug ME input by the user are within the range of the previously set dose limit value 83 and administration rate limit value 84. (Step S8). When the input value is out of the range of the respective limit values 83 and 84 (step S8: No), the administration condition determination unit 50a displays an error indicating that the input dose or administration rate exceeds the limit value, and also displays an error. Return to step S7.

On the other hand, when the input dose or administration rate is within the limit value range (step S8: Yes), the syringe pump 10 starts administration of the drug ME (step S9: administration step). By the above treatment, the pre-stage treatment flow up to the start of administration of the drug ME is completed.

When the administration of the drug ME is started, the syringe drive control unit 52 of the syringe pump 10 drives the drive source 34 based on the set dose and administration rate of the drug ME. As a result, the pusher drive mechanism 32 is driven, and the movable body 44 pushes the plunger 16 into the syringe body 14, so that the drug ME is discharged from the syringe pump 10. The drug ME is successfully administered to the patient via tube 18.

If the measured absorption spectrum AS and the determination absorption spectrum JS do not match in step S4 (step S4: No), the drug ME stored in the syringe 12 is not registered in step S10. This is displayed on the monitor 40. When step S10 is performed, the syringe pump 10 ends the pre-stage processing flow. The syringe pump 10 may be prohibited from administering the drug ME with the implementation of step S10.

As described above, according to the syringe pump 10 and the drug administration method of the syringe pump 10 according to the present embodiment, the optical measurement unit 38 performs optical measurement on the syringe 12 to identify the drug ME, so that the apparatus can be used. It is possible to directly identify the drug ME to be actually administered. As a result, it is possible to more reliably prevent erroneous administration of the drug ME, and by eliminating the need for the conventional confirmation method using a barcode or IC tag, the time and effort required to use the barcode or IC tag can be reduced. The cost can be reduced. Alternatively, even when the confirmation method using a barcode or IC tag is used together, the drug ME should be appropriately administered by preventing the identification code from being affixed to the container and the drug ME to be selected incorrectly due to improper reading of the identification code. Can be done.

In this case, the syringe pump 10 can acquire the optical characteristics of the drug ME consisting of the distribution of wavelength and absorbance by analyzing the signal of the optical measurement unit 38 by the analysis unit 72 and obtaining the measured absorbance spectrum AS. .. Therefore, the drug identification unit 74 refers to the drug database 80 to determine whether the measured absorption spectrum AS matches (or approximates) or does not match (or approximates) the determination absorption spectrum JS. Each can be determined easily and quickly.

Further, the drug identification unit 74 can easily determine that the drug ME is not registered in the drug database 80, and can notify the user to that effect. As a result, the user can take necessary measures. The analysis unit 72 can obtain an accurate measured absorption spectrum AS by removing the absorption spectrum of the syringe body 14. Further, the syringe pump 10 can appropriately administer the drug ME to the administration target by setting the dose limit value 83 or the administration rate limit value 84 of the drug ME based on the specified drug ME.

Furthermore, the syringe pump 10 measures the drug ME of the syringe 12 in the state of being set in the apparatus main body 20 by arranging the optical measuring unit 38 at a position facing the syringe 12 (built in the case 22). can do. This makes it possible to more reliably identify the drug ME and prevent erroneous administration. Then, the measuring unit control unit 54 drives the optical measuring unit 38 as the syringe 12 is set in the device to automatically perform the optical measurement, so that it is possible to prevent the user from forgetting to operate the syringe. Twelve drug MEs can be identified. In addition, the user's operation is simplified and the usability of the device is improved.

The present invention is not limited to the above-described embodiment, and various modifications can be made according to the gist of the invention. For example, the syringe pump 10 is not limited to the syringe 12 as a storage unit set in the device main body 20, and various containers capable of storing the drug ME may be applied, and the mechanism for discharging the drug ME from the device main body 20 may be applied. An appropriate one may be used depending on the container. For example, a flexible packaging bag can be used as the storage unit, and a mechanism for discharging the drug ME from the packaging bag by crushing the packaging bag can be adopted.

Further, for example, the syringe pump 10 may be provided with the optical measuring unit 38 in a housing (not shown) different from the apparatus main body 20 to specify the syringe 12 or the drug ME of the vial before being set in the arranging unit 24. .. In this case, it is preferable to adopt a configuration in which the apparatus main body 20 and the housing of the optical measurement unit 38 are assembled and integrated with each other at the time of storage, and the optical measurement unit 38 is removed at the time of measurement.

Further, when the syringe pump 10 specifies the concentration of the drug ME together with the type of the drug ME at the time of specifying the drug specifying unit 74, the information on the concentration may be displayed on the monitor 40. By confirming the concentration, the user can determine whether or not the concentration of the drug ME to be administered is correct. For example, by identifying the insulin concentration and displaying the insulin titer, the user can review whether or not the insulin concentration to be administered is correct.

Alternatively, the drug administration device 10 can be applied to various devices other than the syringe pump 10, and as an example thereof, as shown in FIG. 6, an infusion set 94 including an infusion bag 90 and an infusion tube 92. Liquid transfer pump 96 can be mentioned.

This type of liquid feed pump 96 is provided at an intermediate position of the infusion tube 92, and allows the drug solution to flow through the infusion tube 92. In specifying the drug ME, it is preferable to provide a storage unit (not shown) for temporarily retaining the drug ME inside the liquid feed pump 96, and to identify the drug ME flowing in the storage unit by optical measurement. When the drug ME is specified, the liquid feed pump 96 may determine whether or not the liquid feed amount and the liquid feed rate of the drug ME are normal. On the other hand, when it is determined that the drug ME is not registered in the liquid feed pump 96, it is advisable to stop the administration of the drug ME.

Further, as shown by the dotted line in FIG. 6, the drug administration device (liquid transfer pump 96a) is directly attached to the infusion bag 90 to perform optical measurement on the drug ME in the infusion bag 90 (storage unit). It may be configured.

10 ... Drug administration device (syringe pump) 12 ... Syringe 20 ... Device body 24 ... Arrangement unit 26 ... Mechanism unit 32 ... Pusher drive mechanism 34 ... Drive source 36 ... Control circuit 38 ... Optical measurement unit 40 ... Monitor 50 ... Administration parameters Setting unit 52 ... Syringe drive control unit 54 ... Measurement unit Control unit 70 ... Drug determination processing unit 72 ... Analysis unit 74 ... Drug identification unit 76 ... Specific post-processing unit 80 ... Drug database 96, 96a ... Liquid feed pump AS ... Measurement absorption Spectrum JS ... Absorption spectrum for judgment ME ... Drug

Claims (8)

A drug administration device that administers the drug stored in the syringe to the supply target.
An optical measurement unit that performs optical measurement on the syringe,
A control unit that analyzes the signal output by the syringe to identify the drug in the syringe, and
A notification unit that notifies information on the drug of the syringe specified by the control unit, and a notification unit.
A light guide path provided between the light emitting element and the light receiving element of the optical measuring unit and the syringe body of the syringe.
Is fixed to the syringe body, said by shielding the portion contacting holding the syringe body, characterized in that it comprises a holder to assist the optical measurement of the optical measuring section and shielding the light path Drug administration device. In the drug administration device according to claim 1,
The control unit includes an analysis unit that analyzes the signal of the optical measurement unit to obtain a measurement absorption spectrum which is a distribution of wavelength and absorbance.
A drug administration device comprising: a drug identification unit for specifying a drug of the syringe based on the measured absorption spectrum. In the drug administration device according to claim 2,
The drug identification unit refers to a drug database in which a plurality of types of drug information including a unique determination absorption spectrum for determining the measured absorption spectrum are registered.
A drug administration device for identifying a drug in the syringe based on the measurement absorption spectrum matching or approximating the determination absorption spectrum. In the drug administration device according to claim 3,
When the drug identification unit determines that all the measured absorption spectra do not match the plurality of determination absorption spectra stored in the drug database, the control unit uses the notification unit to perform the determination. A drug administration device characterized by notifying that a drug in a syringe is not registered. In the drug administration device according to any one of claims 2 to 4.
The analysis unit is a drug administration device characterized by removing the absorption spectrum of the syringe when analyzing the signal. In the drug administration device according to any one of claims 1 to 5.
The control unit sets a limit value of a dose or a dose rate corresponding to the specified drug in the syringe to limit a range of the dose or rate of the drug set by the user. Dosing device. In the drug administration device according to any one of claims 1 to 6.
The drug administration device is characterized in that the optical measurement unit is arranged at a position facing the syringe in a state of being set in the device. In the drug administration device according to claim 7.
The control unit includes a measurement unit control unit that drives the optical measurement unit to automatically perform the optical measurement when the syringe is set in the device.

Images